Differential effects of 19-nor-1,25-(OH)2D2 and 1α-hydroxyvitamin D2 on calcium and phosphorus in normal and uremic rats

Kidney International

Volumn 62, Issue 4, 2002, Pages 1277-1284

  Slatopolsky, Eduardo ^a   Cozzolino, Mario ^a   Finch, Jane L ^a  

^a Renal Division   (United States)

Author keywords

Calcitriol analogs; Chronic renal failure; Hemodialysis; PTH; Secondary hyperparathyroidism; Uremia; Vitamin D

Indexed keywords

1,25 DIHYDROXYERGOCALCIFEROL; CALCIUM; DOXERCALCIFEROL; PARICALCITOL; PHOSPHORUS;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CALCIUM ABSORPTION; CALCIUM BLOOD LEVEL; CALCIUM DEFICIENCY; CALCIUM EXCRETION; CALCIUM METABOLISM; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; FEMALE; INTESTINE ABSORPTION; NONHUMAN; PARATHYROIDECTOMY; PHOSPHATE BLOOD LEVEL; PHOSPHATE METABOLISM; PRIORITY JOURNAL; RAT; TREATMENT OUTCOME; UREMIA; URINARY EXCRETION;

EID: 0036380963     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.2002.00573.x     Document Type: Article

References (53)

1. SILVER J, RUSSELL J, SHERWOOD LM: Regulation by vitamin D metabolites of messenger RNA for pre-pro-parathyroid hormone in isolated bovine parathyroid cells. Proc Natl Acad Sci USA 82:4270-4273, 1985
2. 2D of transcription of the parathyroid hormone gene. Endocrinology 119:2864-2866, 1985
3. 3 suppresses PTH secretion from bovine parathyroid cells in tissue culture. Endocrinology 117:2114-2119, 1985
4. CHAN YL, MCKAY C, DYE E, et al: The effect of 1,25-dihydroxycholecalciferol on parathyroid hormone secretion by monolayer cultures of bovine parathyroid cells. Calcif Tissue Int 38:27-32, 1986
5. SLATOPOLSKY E, WEERTS C, THIELAN J, et al: Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxycholecalciferol in uremic patients. J Clin Invest 74:2136-2143, 1984
6. DELMEZ JA, TINDIRA C, GROOMS P, et al: Parathyroid hormone suppression by intravenous 1,25-dihydroxyvitamin D: A role for increased sensitivity to calcium. J Clin Invest 83:1349-1355, 1989
7. ANDRESS DL, KEITH MD, NORRIS C, et al: Intravenous calcitriol in the treatment of refractory osteitis fibrosa of chronic renal failure. N Engl J Med 321:274-279, 1989
8. GALLIENI M, BRANCACCIO D, PADOVESE P, et al: Low-dose intravenous calcitriol treatment of secondary hyperparathyroidism in hemodialysis patients. Kidney Int 42:1191-1198, 1992
9. CANNELLA G, BONUCCI E, ROLLA D, et al: Evidence of healing of secondary hyperparathyroidism in chronically hemodialyzed uremic patients treated with long-term intravenous calcitriol. Kidney Int 46:1124-1132, 1994
10. SLATOPOLSKY E, WEERTZ C, LOPEZ-HILKER S, et al: Calcium carbonate as a phosphate binder in patients with chronic renal failure undergoing dialysis. N Engl J Med 315:157-161, 1986
11. BIKLE DD: Clinical counterpoint: Vitamin D: New actions, new analogs, new therapeutic potential. Endocrine Rev 13:765-784, 1992
12. BROWN AN, DUSSO A, SLATOPOLSKY E: Selective vitamin D analogs and their therapeutic applications. Semin Nephrol 14:156-174, 1994
13. NORMAN AW: The vitamin D endocrine system: Manipulation of structure-function relationships to provide opportunities for development of new cancer chemopreventive and immunosuppressive agents. J Cell Biochem 22:S218-S225, 1995
14. 3: Preferential activity in inducing differentiation of human leukemia cells HL-60 in vitro. Proc Natl Acad Sci USA 84:2610-2614, 1987
15. BINDERUP L, BRAMM E: Effects of a novel vitamin D analogue MC903 on cell proliferation and differentiation in vitro and on calcium metabolism in vivo. Biochem Pharmacol 37:889-895, 1988
16. ZHOU JY, NORMAN AW, LUBBERT M, et al: Novel vitamin D analogs that modulate leukemic cell growth and differentiation with little effect on either intestinal calcium absorption or bone calcium mobilization. Blood 74:82-93, 1989
17. 3 with an oxygen atom in their side chain. Biochem Int 19:1143-1149, 1989
18. 3 analogues on the proliferation and differentiation of cultured human keratinocytes, calcium metabolism, and the differentiation of human HL-60 cells. J Nutr Biochem 4:49-57, 1993
19. 3, inhibits the growth of human breast cancer in vitro and in vivo without causing hypercalcemia. Endocrinology 129:832-837, 1991
20. 3, a potent angiogenesis inhibitor, on rat mammary tumors induced by 7,12-dimethylbenz[a]-anthracene. Anticancer Drugs 2:475-480, 1991
21. COLSTON KW, CHANDER SK, MACKAY AG, et al: Effects of synthetic vitamin D analogues on breast cancer cell proliferation in vivo and in vitro. Biochem Pharmacol 44:693-702, 1992
22. 3, is a potent modulator of in vivo immunoregulating activity without inducing hypercalcemia in mice. Endocrinology 124:2545-2647, 1989
23. 2, suppresses parathyroid hormone secretion in uremic rats in the absence of hypercalcemia. Am J Kid Dis 26:852-860, 1995
24. 2, suppresses PTH and parathyroid gland growth in uremic rats without elevation of intestinal vitamin D receptor content. Am J Kid Dis 30:105-112, 1997
25. 2 in hemodialysis patients with moderate to severe secondary hyperparathyroidism. Kidney Int 51:317-323, 1997
26. 2) in dialysis patients with secondary hyperparathyroidism: A sequential comparison. Am J Kid Dis 37:532-543, 2001
27. RITZ E, SCHOMIG M, BOMMER J: Osteodystrophy in the millennium. Kidney Int 56(Suppl 73):S94-S98, 1999
28. DRUEKE TB: Renal osteodystrophy: Management of hyperphosphatemia. Kidney Int 15:32-33, 2000
29. HRUSKA K: Pathophysiology of renal osteodystrophy. Pediatr Nephrol 14:636-640, 2000
30. 2 (Paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis. J Am Soc Nephrol 9:1427-1432, 1998
31. 2 on intestinal calcium and phosphorus absorption. J Lab Clin Med 139:279-284, 2002
32. 2 on calcium and phosphorus resorption in bone. J Am Soc Nephrol 10:980-985, 1999
33. 3. Am J Physiol 254:E402-E406, 1988
34. 2, and epimer. Arch Biochem Biophys 273:64-71, 1989
35. 2, a vitamin D analog with reduced bone resorbing activity in vitro. J Am Soc Nephrol 11:1857-1864, 2000
36. LACEY DL, TIMMS E, TAN HL, et al: Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93:165-176, 1998
37. YASUDA H, SHIMA N, NAKAGAWA N, et al: Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclasto-genesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 95:3597-3602, 1998
38. FULLER K, WONG B, CHOI YW, et al: TRANCE is necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts. J Exp Med 188:997-1001, 1998
39. 3, in Vitamin D, edited by FELDMAN D, GLORIEUX F, PIKE W, San Diego, Academic Press, 1997, pp 13-32
40. 3. J Am Vet Med Assoc 182:1358-1369, 1989
41. 3 in the rat. Proc Soc Exp Biol Med 178:432-436, 1985
42. 2 in mammals. Biochemistry 29:578-582, 1990
43. 2 detectable in human serum. J Clin Endocrin Metabol 83:2156-2166, 1998
44. 3 are associated with enhanced activation of the vitamin D receptor. J Biol Chem 270:10551-10558, 1995
45. TAKEYAMA K, MASUHIRO Y, FUSE H, et al: Selective interaction of vitamin D receptor with transcriptional coactivators by a vitamin D analog. Mol Cell Biol 19:1049-1055, 1999
46. 3 are highly potent inducers of DRIP coactivator complex binding to the vitamin D receptor. J Biol Chem 274:16838-16848, 1999
47. QUACK M, CARLBERG C: Selective recognition of vitamin D receptor conformations mediates promoter selectivity of vitamin D analogs. Mol Pharmacol 55:1077-1087, 1999
48. US RENAL DATA SYSTEM: USRDS 1999 Annual Data Report. Bethesda, The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 1999
49. BLOEMBERGEN WE: Cardiac disease in chronic uremia. Epidemiol Adv Ren Replac Ther 4:185-193, 1997
50. HUTING J: Mitral valve calcification as an index of left ventricular dysfunction in patients with end stage renal disease on peritoneal dialysis. Chest 105:383-388, 1994
51. RIBEIRO S, RAMOS A, BRANDAO A, et al: Cardiac valve calcification in haemodialysis patients: Role of calcium-phosphate metabolism. Nephrol Dial Transplant 13:2037-2040, 1998
52. ANDRESS DL: New therapies raise new issues for lowering parathyroid hormone levels in uremic patients. Semin Dial 12:282-284, 1999
53. BLOCK GA, PORT FK: Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: Recommendations for a change in management. Am J Kid Dis 6:1226-1237, 2000